Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

Inclusion Criteria: * Body mass index (BMI) must be ≥19 to \<45 kg/m\^2 at the Screening Visit * Participant must have uncontrolled hypertension defined as meeting both of the following criteria: * The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period * The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3) * The participant must have Stage 3b (eGFR \[EPI\] ≥30 and ≤44 mL/min/1.73 m\^2) or Stage 4 (eGFR \[EPI\] ≥15 and \<30 mL/min/1.73 m\^2) CKD. Exclusion Criteria: * Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period * Participant has a serum potassium level \>4.8 mmol/L during the Screening or Run-In Periods * Participant has had a serum potassium level \>5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1) * Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3) * Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period a…